• Insilico Medicine received China NMPA IND clearance for ISM8969/HT-001, an oral blood-brain-barrier-penetrant NLRP3 inhibitor for Parkinson’s disease.
• The program is co-developed with Hygtia Therapeutics, enabling parallel clinical evaluation in China alongside an ongoing Phase 1 study in Australia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12265646), on August 03, 2026, and is solely responsible for the information contained therein.